Biotechnology company developing targeted cellular degradation therapeutics by reprogramming the autophagy pathway
Biotechnology company developing targeted cellular degradation therapeutics by reprogramming the autophagy pathway. Its PHLYT™ platform directs disease-causing cellular targets—including organelles, protein aggregates, and large signaling complexes—to lysosomes for degradation, with potential applications in oncology, inflammation, neurodegeneration, and metabolic disorders.